<DOC>
	<DOCNO>NCT01416493</DOCNO>
	<brief_summary>This proof concept study ask alkaline phosphatase injection reduce acute inflammation rheumatoid arthritis patient .</brief_summary>
	<brief_title>Bovine Intestinal Alkaline Phosphatase ( bIAP ) Modulating Rheumatoid Arthritis</brief_title>
	<detailed_description>This proof concept study establish safety subcutaneous ( sc ) treatment efficacy alkaline phosphatase ( AP ) reduce specific pro-inflammatory cytokine 3 day twice daily s.c. treatment . A total dose 12000 Units AP administer 2000 IU s.c. injection twice daily 3 day . Subjects closely follow 8 day regular clinical observation make 3 month . Close 3 month initiation treatment .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Male nonpregnant , nonlactating female patient race age &gt; 18 year . Woman childbearing potential must regular contraceptive throughout trial ( Pregnancy test ) . 1A : RA accord 1987 revise ARA criterion ( Arnett 1987 ) active disease DAS28 &gt; 3.2 despite prior concurrent use DMARDs . 2 . Patients may active therapy may continuous DMARD therapy include Methotrexate , Sulphasalazine , Leflunomide , Hydroxychloroquine , Myocrisin alone combination , NSAID treatment , steroid ( prednisolone 10mg/day ) . 3 . Patients must measurable acute phase response : CRP ( &gt; 10mg/dl ) , ESR &gt; 25 . ( measured routine lab range CRP/ ESR/AP/ standard biochemistry ) 4 . Patients eligible treatment biological TNFα blocker await administration treatment may enroll laboratory safety protocol Data Clinical Phase observation collect handle last observation carry forward final record prior administration TNF block agent , occur within 3month Clinical Phase . The administration TNFα blocker delay protocol . 5 . Patients give write informed consent prior participation trial undertake comply protocol . 1 . Patients unwilling unable fully evaluate followup . 2 . Patients active infection suspect systemic infection patient treat antibiotic . 3 . Patients whose screen blood reflect sufficient cytokine acute phase response . 4 . Patients evidence significant hepatic disease , include history clinical sign laboratory value total bilirubin &gt; 34.2 umol/L ( &gt; 2.0 mg/dL ) , ALT ( &gt; 120 ) AST ( &gt; 135 ) correspond &gt; 3X upper limit normal . 5 . Alkaline phosphatase level must less 145 IU/L ( routine clinical method ) 6 . Patients receive investigational drug 30 day prior study drug administration , currently participate study administration investigational drug within one month anticipate . 7 . Patients renal insufficiency ( history creatinine &gt; 177umol/L &gt; 2.0 mg/dL ) chronic renal failure require dialysis . 8 . Patients severe neurological deficit ( see Appendix I ) . 9 . Patients recent history drug substance alcohol abuse . 10 . Patients diagnosis idiopathic thrombocytopenia . 11 . Patients history cancer receive chemotherapy radiation therapy within past 3 month . Patients receive adjuvant hormonal therapy exclude . If cancer resolve completely , patient enrol without permission Alloksys . 12 . Patients receive oral glucocorticoid &gt; 10mg /day IV , IM Intra articular dosing within 30 day commence protocol . 13 . Patients vegetarians veganists patient may expect tolerant bovine protein , wish exposure bovine proteins personal reason . 14 . Patients , opinion Investigator Sponsor , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>acute rheumatoid arthritis</keyword>
</DOC>